Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer; and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:
(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2010 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delay in Diagnosis and Referral Patterns of 646 Patients with Oral and Maxillofacial Cancer: A Report from a Single Institution in Hamburg, Germany. R.E. FRIEDRICH (Hamburg, Germany)</td>
<td>1833</td>
</tr>
<tr>
<td>Prevalence of CA 27.29 in Primary Breast Cancer Patients before the Start of Systemic Treatment. B. RACK, C. SCHINDLBECK, J. JÜCKSTOCK, E.-M. GENSS, P. HEPP, R. LORENZ, H. TESCH, A. SCHNEEWEISS, M.W. BECKMANN, W. LICHTENEGGER, H. SOMMER, K. FRIESE, W. JANNI; for the SUCCESS Study Group (Muenchen; Duesseldorf; Braunschweig; Frankfurt; Heidelberg; Erlangen; Berlin, Germany)</td>
<td>1837</td>
</tr>
<tr>
<td>Distant Metastases and Malignant Cellular Neoplasms Encountered in the Oral and Maxillofacial Region: Analysis of 92 Patients Treated at a Single Institution. R.E. FRIEDRICH, M. ABADI (Hamburg, Germany)</td>
<td>1843</td>
</tr>
<tr>
<td>Expression of the Carbohydrate Tumor Marker Sialyl Lewis a (Ca19-9) in Squamous Cell Carcinoma of the Larynx. I. WIEST, C. ALEXIOU, D. MAYR, S. SCHULZE, C. KUHN, S. KUNZE, M. BÜTTNER, P. BETZ, U. JESCHKE (Munich; Erlangen, Germany)</td>
<td>1849</td>
</tr>
<tr>
<td>Clinical Relevance of Thymidine Kinase for the Diagnosis, Therapy Monitoring and Prognosis of Non-operable Lung Cancer. S. HOLDENRIEDER, J. VON PAWEL, T. DUELL, K. FELDMANN, H. RAITH, A. SCHOLLEN, D. NAGEL, P. STIEBER (Munich; Gauting; Germany)</td>
<td>1855</td>
</tr>
<tr>
<td>Review: Metabolism in Cancer Patients. J. ARENDS (Freiburg, Germany)</td>
<td>1863</td>
</tr>
<tr>
<td>CA19-9 Serum Concentrations – Analysis of the Serum Kinetics During First-line Therapy of Pancreatic Cancer in Relation to Overall Survival. R. KLPDOR, M. BAHLO, A. BABINSKI, S. KLAPDOR (Hamburg, Germany)</td>
<td>1869</td>
</tr>
</tbody>
</table>

* Reviews (pages 1767, 1863)
Clinical and Surgical Experience with Wilms’ Tumor. Long-term Results of a Single Institution. V. ZUGOR, G.E. SCHOTT, B. LAUSEN, R. KÜHN, A.P. LABANARIS (Gronau; Erlangen, Nürnberg, Germany) ........................................... 1735

Usefulness of Combined FDG-PET with CT or Tumour Markers in Lung Cancer Diagnosis. K. KLEY, P. OEHR (Bonn, Germany) .................................................................................................................. 1741

Solitary Testicular Metastasis from Prostate Cancer: A Rare Case of Isolated Recurrence after Radical Prostatectomy. S. JANSSEN, J. BERNHARDS, A. G. ANASTASIADIS, F. BRUNS (Hannover; Gehrden; Großburgwedel, Germany) .................................................................................................................. 1747

Dysplasia of the Orbit and Adjacent Bone Associated with Plexiform Neurofibroma and Ocular Disease in 42 NF-1 Patients. R.E. FRIEDRICH, C. STELLJES, C. HAGEL, M. GIESE, H.A. SCHEUER (Hamburg, Germany) ................................................................. 1751

Vascular Endothelial Growth Factor (VEGF) in Sera of Oral and Oropharyngeal Squamous Cell Carcinoma Patients. R.E. FRIEDRICH, R. KLAPDOR, C. HAGEL, S. BARTEL-FRIEDRICH (Hamburg; Halle, Germany) ....................................................................................................................... 1765

* Short Review: Evidence-based Complementary Oncology: Innovative Approaches to Optimise Standard Therapy Strategies. J. BEUTH (Cologne, Germany) ................................................................. 1767

IL-6 and VEGF in Small Cell Lung Cancer Patients. E. WÓJCIK, J. JAKUBOWICZ, P. SKOTNICKI, B. SAS-KORCZYŃSKA, J.K. KULPA (Cracow, Poland) .......................................................................................................................... 1773

Extramedullary Plasmocytoma: A Rare Case with Bifocal Manifestation at Uncommon Sites. F. BRUNS, S. JANSSEN, F. LAENGER, C. DOBBELSTEIN, A. MEYER (Hannover, Germany) ............................................................................................................. 1779

Selenium Substitution During Radiotherapy of Solid Tumours – Laboratory Data from Two Observation Studies in Gynaecological and Head and Neck Cancer Patients. J. BÜNTZEL, O. MICKE, K. KISTERS, F. BRUNS, M. GLATZEL, K. SCHÖNEKAES, G. KUNDT, U. SCHÄFER, R. MÜCKE (Nordhausen; Bielefeld; Hannover; Suhl; Rostock; Lemgo, Germany) ........................................................................................................... 1783

Adenomatoid Odontogenic Tumour of the Mandible. R.E. FRIEDRICH, J. ZUSTIN, H.A. SCHEUER (Hamburg, Germany) ................................................................. 1787

Dermal Cylindroma of the Scalp (Turban Tumour) and Subjacent Calvarian Defects. R.E. FRIEDRICH (Hamburg, Germany) ....................................................................................................................... 1793

Serum S100B and LDH Are Not Useful in Predicting the Sentinel Node Status in Melanoma Patients. F. EGBERTS, A. MOMKVIST, J.-H. EGBERTS, K.C. KAehler, A. HAUSCHILD (Kiel, Germany) ........................................... 1799


Appendices of the Nipple and Areola of the Breast in Neurofibromatosis Type 1 Patients Are Neurofibromas. R.E. FRIEDRICH, C. HAGEL (Hamburg, Germany) .......................................................................................................................... 1815

Mental Neuropathy (Numb Chin Syndrome) Leading to Diagnosis of Metastatic Mediastinal Cancer. R.E. FRIEDRICH (Hamburg, Germany) ....................................................................................................................... 1819

Negative Predictive Value of Systematic Ultrasound-guided Prostate Biopsy: Which Tumours Do We Miss? T. KÖPKE, F. OBERPENNING, O. BETTENDORF, E. ELITZE, E. HERRMANN, L. HERTLE, C. WEINING, C. WULFING, A. SEMJONOW (Münster; Bocholt, Germany) .......................................................................................................................... 1823

Contents continued on the preceding page
Centre-independent Detection of Non-small Cell Lung Cancer (NSCLC) by Means of Classification with Receiver Operating Characteristic (ROC)-based Data Transformation. N. BITTERLICH, T. MULEY, J. SCHNEIDER (Chemnitz; Heidelberg; Giessen, Germany) .......................................................... 1661

Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors. L. BENESOVA, M. MINARIK, D. JANCARIKOVA, B. BELSANOVA, M. PESEK (Prague; Pilsen, Czech Republic) ................................................................. 1667

Prostaglandin Metabolising Enzymes and PGE\textsubscript{2} are Inversely Correlated with Vitamin D Receptor and 25(OH)\textsubscript{2}D\textsubscript{3} in Breast Cancer. M. THILL, D. FISCHER, F. HOELLEN, K. KELLING, C. DITTMER, S. LANDT, D. SALEHIN, K. DIEDRICH, M. FRIEDRICH, S. BECKER (Luebeck; Krefeld; Essen, Germany) ......................... 1673

Osteopontin (OPN) Expression in Thyroid Carcinoma. J. BRIESE, S. CHENG, S. EZZAT, W. LIU, D. WINER, C. WAGENER, A.-M. Bamberger, S.L. ASA (Toronto, ON, Canada; Hamburg, Germany) ...... 1681


Clinical Studies


CEA-, Her2/neu-, BCRP- and Hsp27-positive Microparticles in Breast Cancer Patients. S. LIEBHARDT, N. DITSCH, R. NIEUWLAND, A. RANK, U. JESCHKE, F. VON KOCH, K. FRIESE, B. TOOTH (Munich; Heidelberg, Germany; Amsterdam, Netherlands) ......................................................... 1707

Thyroid Function in Breast Cancer Patients. N. DITSCH, S. LIEBHARDT, F. VON KOCH, M. LENHARD, M. VOGESER, C. SPITZWEB, J. GALLWAS, B. TOOTH (Munich; Heidelberg, Germany) .......................................................... 1713

Anal Cytology as a Screening Tool for Early Detection of Anal Dysplasia in HIV-infected Women. A. GINGELMAIER, T. WEISSENBACHER, B. KOST, R. KAESTNER, M. SOVRIC, I. MYLONAS, K. FRIESE, F. BERGAUER (Munich, Germany) .......................................................... 1719

Primary Leiomyosarcoma of the Testis. A Case Report. A.P. LABANARIS, V. ZUGOR, R. SMISZEK, R. NÜTZEL, R. KUHN (Nürnberg; Gronau, Germany) .......................................................... 1725

Simulation of Scattering Effects of Irradiation on Surroundings Using the Example of Titanium Dental Implants: A Monte Carlo Approach. R.E. FRIEDRICH, M. TORDROVIC, A. KRÜLL (Hamburg, Germany) .................................................................................. 1727

Congenital Juvenile Granulosa Cell Tumor of the Testis in Newborns. V. ZUGOR, A.P. LABANARIS, J. WITT, A. SEIDLER, K. WEINGÄRTNER, G.E. SCHOTT (Gronau; Nürnberg; Bamberg; Erlangen, Germany) ............................................................................................. 1731
Generation of an Antibody against the Protein Phosphatase 1 Inhibitor KEPI and Characterization of the Epitope. K. DASKALOW, P. BOISIGUERIN, B. JANDRIG, F.K.H. VAN LANDEGHEM, R. VOLKMER, B. MICHEEL, J.A. SCHENK (Golm; Berlin; Potsdam; Bonn, Germany) ................................................................. 1573

TP53 Gene Mutations in Prostate Cancer Progression. T.H. ECKE, H.H. SCHLECHTE, K. SCHIEMENZ, M.D. SACHS, S.V. LENK, B.D. RUDOLPH, S.A. LOENING (Bad Saarow; Berlin, Germany) .................. 1579

Online Monitoring of Cellular Metabolism in the MCF-7 Carcinoma Cell Line Treated with Phytoestrogen Extracts. S. ABARZUA, S. DRECHSLER, K. FISCHER, N. PIETSCHEMMANN, J. STAPEL, S. DUDA, D.-U. RICHTER, R. EHRET, B. PIECHULLA, V. BRIESE (Rostock, Germany) .............................. 1587

Expression and Distribution of Tenascin in Rat Submandibular Glands Following Irradiation. S. BARTEL-FRIEDRICH, C. LAUTENSCHLÄGER, H.-J. HOLZHAUSEN, R.E. FRIEDRICH (Halle; Hamburg, Germany) ............................... 1593

Glycodelin Expression in Correlation to Grading, Nodal Involvement and Steroid Receptor Expression in Human Breast Cancer Patients. C. SCHOLZ, B. TOTH, E. BARTHIEL, I. MYLONAS, T. WEISSENBACHER, K. FRIESE, U. JESCHKE (Munich, Germany) ................................................................. 1599

Basaloid Lesions of Oral Squamous Epithelial Cells and their Association with HPV Infection and P16 Expression. R.E. FRIEDRICH, C. SPERBER, T. JÄKEL, K. RÖSER, T. LÖNING (Hamburg, Germany) .................................................. 1605

Long-term Stability of Circulating Nucleosomes in Serum. S. HOLDENRIEDER, J. VON PAWEL, D. NAGEL, P. STIEBER (Munich; Gauting, Germany) ................................................................. 1613

Coexpression of MAGE-A Peptides and HLA Class I Molecules in Hepatocellular Carcinoma. N. ROCHE, A. KUTUP, Y. VASHIST, E. YEKEBAS, V. KALININ, J.R. IZBICK (Hamburg, Germany) .................. 1617

Morphometrics of the Facial Nerve Following Fractionated External Irradiation: An Experimental Study in Rats. R.E. FRIEDRICH, K. LASSON, R. LAAS, C. HAGEL, S. BARTEL-FRIEDRICH (Hamburg; Halle, Germany) .................. 1625

Proposal for a Standardized PSA Doubling-time Calculation. A. PONHOLZER, N. POPPER, F. BREITENECKER, H.-P. SCHMID, W. ALBRECHT, W. LOIDL, S. MADERSBACHER, P. SCHRAMEK, A. SEMJONOW, M. RAUCHENWALD (Vienna; Mistelbach; Linz, Austria; St. Gallen, Switzerland; Münster, Germany) ................................................................. 1633

Determination of Glycodelin-A Expression Correlated to Grading and Staging in Ovarian Carcinoma Tissue. A. TSVILIANA, D. MAYR, C. KUHN, S. KUNZE, I. MYLONAS, U. JESCHKE, K. FRIESE (Munich, Germany) ................................................................. 1637

Insulin-like Growth Factor-1 Receptor (IGF-1R) in Primary and Metastatic Undifferentiated Carcinoma of the Head and Neck: A Possible Target of Immunotherapy. R.E. FRIEDRICH, C. HAGEL, S. BARTEL-FRIEDRICH (Hamburg; Halle, Germany) ................................................................. 1641


Expression of Transketolase-like 1 Protein (TKTL1) in Human Endometrial Cancer. M. KROCKENBERGER, J.B. ENGEL, M. SCHMIDT, N. KOHRENHAGEN, S.F.M. HÄUSLER, Y. DOMBROWSKI, M. KAPP, J. DIETL, A. HONIG (Wuerzburg, Germany) ................................................................. 1653

Contents continued on the preceding page